Maurie Markman, MD

Maurie Markman, MD, is president of Medicine & Science at City of Hope Atlanta, Chicago, and Phoenix

Articles

Dr. Markman on Latest Advances in Treatment of Gynecological Malignancies

July 18th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses the latest advances in treatment for gynecological malignancies and other tumor types.

Defining Precision Cancer Medicine the Right Way

July 17th 2018

Maurie Markman, MD, defines precision medicine in oncology.

Inaccurate, Muddled Messages Jeopardize the Public's Trust in Science

June 27th 2018

The public’s faith in science, particularly in efforts related to health, is crucial for the successful implementation of strategies designed to improve the human condition, says Maurie Markman, MD.

Genetic Cancer Risk Assessment: Highly Relevant But Increasingly Complex

June 12th 2018

Maurie Markman, MD, discusses the potential to employ germline data and knowledge about the presence of specific common, uncommon, or rare variants to cancer therapy.

Will Precision Medicine Displace the Randomized Trial?

May 20th 2018

Maurie Markman, MD, sheds light on the debate regarding the future direction of clinical investigation.

Right-to-Try Laws: Let's Move Beyond the Rhetoric

May 15th 2018

Maurie Markman, MD, shares his thoughts on the right-to-try bill, which would allow terminally ill patients to receive investigational drugs that have been studied in phase I trials without applying through the FDA’s expanded access program.

Opioid Epidemic Poses Complex Problem for Cancer Care

May 10th 2018

Maurie Markman, MD, discusses the cause and impact of the opioid addiction epidemic in the United States.

All Is Not Well in the World of Academic Scientific Enterprise

April 28th 2018

It is quite difficult for those not directly involved in the complex world of academic medicine to understand fully the process of individual professional advancement and the values that organizations place on the components required for achieving and maintaining tenure.

HPV Vaccination Should Be Part of Oncology Cost-Reduction Strategy

April 3rd 2018

The impact of staggering increases in the cost of individual antineoplastic agents for patients and the overall healthcare system cannot be overstated, and there appears to be no realistic solution to the current dilemma that is acceptable to the parties involved in this ongoing debate.

Weighing Treatment Risks Versus Benefits Ultimately a Patient Calculation

March 15th 2018

One of the cardinal principles of modern medicine, as practiced in the United States, is active participation by patients—and often their families—in the process of clinical decision making.

Is the Median All We Should Offer Our Patients?

February 28th 2018

Although median survival is a reasonable endpoint to highlight, it is only 1 of many relevant outcome factors to discuss, and, most important, this mathematical figure simply does not define the survival of any particular patient.

Decision Support Is Lacking in Flood of New Data

February 14th 2018

Decision support is only lightly touched upon in the academic oncology papers that are published almost daily suggesting a potential change in paradigms for management in a particular clinical setting.

Dr. Markman on Overall Survival as an Endpoint in Ovarian Cancer Trials

February 7th 2018

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses overall survival as an endpoint in ovarian cancer clinical trials.

Biomarkers Go Beyond "All or None" Equation

January 31st 2018

The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.

Proving "Noninferiority" May Become Another Challenge in Oncology Studies

January 17th 2018

Fewer than 4% of patients with cancer in the United States participate in clinical trials, the elderly and individuals with clinically relevant comorbidities are strikingly underrepresented in the research portfolio.

Missing in Action: Patient Perspective on Cancer Trial Goal

January 14th 2018

There is a critically important subject associated with the clinical trial experience that has had inadequate discussion within the medical literature, regarding the role of the patient beyond agreeing to serve as a research subject.

Where Overall Survival Falls Short as a Gauge

January 9th 2018

From the perspective of a patient and that patient’s family, it is completely understandable that the single most important goal of an antineoplastic strategy is to prolong survival and, if possible, produce a cure.

Don't Rush to Judgment on Off-Label Drug Promotions

January 6th 2018

Controversy over the FDA’s role in regulating off-label marketing practices of pharmaceutical companies continues to reverberate in the medical community.

Precision Medicine Can Help Reduce "Overdiagnosis" Problem

December 27th 2017

In patients with common solid tumors, it is well-established that those with early-stage cancers have a statistically defined superior prognosis compared with those who present with and are required to be treated at later stages of the disease.

Some Common Oncology Terms Carry Unanticipated Consequences

December 26th 2017

There are certain commonly used terms in the realm of oncology that may result in unintended consequences and should be considered carefully before being employed in conversation or in writing.